HUTCHMED (China) Limited
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From HUTCHMED (China) Limited
The US FDA approved Fruzaqla (fruquintinib) for previously treated metastatic disease regardless of biomarker status. The drug, already approved in China, was de-risked when Takeda licensed it from HutchMed.
The emergence of China from API manufacturer to an innovation leader, fuelled by domestic investments and home-grown talent, has been one of the most remarkable trends of the last decade.
Takeda hopes for good news on fruquintinib and TAK-755, while Bristol and SpringWorks share a goal date for their breakthrough-designated cancer treatments.
Excellence, innovation, deal-making and personal achievement across the Japanese biopharma sector were celebrated at the Citeline Pharma Intelligence Awards Japan 2023, held in Tokyo on 17 October.
- Other Names / Subsidiaries
- Hutchison Whampoa
- Sinopharm Pharmaceuticals Company Limited
- Hutchison MediPharma Limited
- Hutchison China MediTech Limited
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.